Pharmaceuticals, Biotechnology and Life Sciences
PARIS–(BUSINESS WIRE)–Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology…
PARIS–(BUSINESS WIRE)–Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology…
PARIS–(BUSINESS WIRE)–Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology…
— MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic…
— MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic…
— MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic…
— MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic…
— MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic…
Celltrion obtains rights for patent, trademark, approval, sales of 18 products in 9 AP markets including South Korea for USD…
Celltrion obtains rights for patent, trademark, approval, sales of 18 products in 9 AP markets including South Korea for USD…